Short- to Mid-term Safety and Efficacy of Prostatic Artery Embolization Using N-Butyl Cyanoacrylate for Symptomatic Benign Prostatic Hyperplasia – A Single-center Experience
Abstract
To assess the safety and efficacy of prostatic artery embolization (PAE) using n-butyl cyanoacrylate (n-BCA) for symptomatic benign prostatic hyperplasia (BPH).
It is retrospective analysis of 17 consecutive patients with symptomatic BPH who underwent PAE using n-BCA at the Department of Peripheral Vascular and Endovascular Sciences, Medanta – The Medicity, Gurugram, Haryana, between January 2020 and December 2023.
The primary outcome assessed was improvement in the International Prostate Symptoms Score (IPSS) from baseline to 12 months. The secondary outcomes assessed were improvements in IPSS-associated quality-of-life score (IPSS-QoL), maximum flow rate on uroflowmetry (Qmax), prostate gland volume (PGV), residual void volume (RVV), and serum prostate-specific antigen (PSA). Adverse events that occurred at any time during the 12-month follow-up were reported according to the Clavien−Dindo grading system.
A total of 17 patients underwent PAE with n-BCA with 100% technical success. There were statistically significant improvements from baseline to 12 months for the IPSS (from 18.41 to 6.35, P < 0.001), IPSS-QoL (from 4.94 to 1.76, P < 0.001), Qmax (from 6.05 to 14.97, P < 0.001), RVV (from 179.7 to 44.7, P < 0.001), PSA level (from 4.06 to 2.06, P < 0.001), and PGV (from 72.2 to 30.5, P < 0.001). There were no major adverse events.
The findings support the safety of PAE using n-BCA, with excellent technical and mid-term clinical outcomes. Randomized trials with longer…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 17 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.